Vikram K. Chand

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · JAMA Oncology · 2020 · 616 citations · Full text

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 429 citations

Second-line Treatment, Afatinib Versus Erlotinib, Medicine +7

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

Mary L. Disis, Matthew H. Taylor, Karen Kelly et al. · JAMA Oncology · 2019 · 417 citations · Full text

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <i>EGFR</i> -Mutant Lung Cancer with and without T790M Mutations

Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen et al. · Cancer Discovery · 2014 · 354 citations · Full text

Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Christophe Le Tourneau, Christopher Hoimes, Corrine Zarwan et al. · Journal for ImmunoTherapy of Cancer · 2018 · 164 citations · Full text